Wells Fargo raised the firm’s price target on Xenon Pharmaceuticals (XENE) to $68 from $49 and keeps an Overweight rating on the shares. The firm says X-TOLE2 data looks good, and while it awaits additional details, Wells thinks azetukalner is approvable in focal-onset seizures, competitive with cenobamate, and sets a high bar for vormatrigine.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XENE:
- Biohaven price target raised to $27 from $24 at Goldman Sachs
- Xenon Pharmaceuticals price target raised to $75 from $52 at Goldman Sachs
- Xenon Pharmaceuticals price target raised to $74 from $53 at H.C. Wainwright
- Xenon Pharmaceuticals price target raised to $90 from $56 at Deutsche Bank
- Xenon Pharmaceuticals Launches $500 Million Public Share Offering